Long-Term Survival in Patients Receiving a Continuous-Flow Left Ventricular Assist Device.


Journal Article

BACKGROUND: Long-term survivors after implantation of left ventricular assist devices (LVADs) are increasing in prevalence. We describe the characteristics and outcomes in patients surviving longer than 4 years on LVAD support. METHODS: We performed a multicenter, retrospective analysis of patients surviving at least 4 years on continuous-flow LVAD (CF-LVAD) support with a HeartMate II at centers participating in the Evolving Mechanical support Research Group. RESULTS: Between 2005 and 2010, 156 long-term survivors were identified with a mean survival of 7.1 years (95% confidence interval: 6.7 to 7.5 years). The mean age was 58.2 ± 15.2 years and 30.1% were women. Readmission rate was low at 1.1 events per patient per year with the most common reasons leading to readmission being infection (0.10 readmissions per patient per year) and gastrointestinal bleeding (0.07 readmissions per patient per year). Two years after implantation, 97% of patients were either New York Heart Association functional class I or II, with 92% at 4 years. CONCLUSIONS: Patients surviving 4 years on CF-LVAD support can anticipate ongoing long-term survival with sustained improvements in functionality and low rates of rehospitalization.

Full Text

Duke Authors

Cited Authors

  • Gosev, I; Kiernan, MS; Eckman, P; Soleimani, B; Kilic, A; Uriel, N; Rich, JD; Katz, JN; Cowger, J; Lima, B; McGurk, S; Brisco-Bacik, MA; Lee, S; Joseph, SM; Patel, CB; Evolving Mechanical Support Research Group (EMERG) Investigators,

Published Date

  • March 2018

Published In

Volume / Issue

  • 105 / 3

Start / End Page

  • 696 - 701

PubMed ID

  • 29198630

Pubmed Central ID

  • 29198630

Electronic International Standard Serial Number (EISSN)

  • 1552-6259

Digital Object Identifier (DOI)

  • 10.1016/j.athoracsur.2017.08.057


  • eng

Conference Location

  • Netherlands